HomeAI · summaries
Storia in 6 fonti
First-in-Class Drug Wins FDA Approval for Polycythemia Vera
Rusfertide mimics hepcidin to target erythrocytosis in rare blood malignancy
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
FDA approves Takeda, Protagonist drug as first treatment for rare blood disorder
FDA approved Takeda & Protagonist's Mimrylo (rusfertide) for polycythemia vera, a rare blood disease.
- ·
morningstar.com
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
